New hope for tough pancreatic tumors: experimental drug added to standard chemo
NCT ID NCT05546853
Summary
This study tested whether adding an experimental drug called NP137 to standard chemotherapy (mFOLFIRINOX) is safe and might work better for people with advanced pancreatic cancer that cannot be removed by surgery. The main goal was to check for side effects in about 43 patients. Researchers also looked to see if the combination helped shrink tumors, extend life, or improve quality of life compared to expectations with standard treatment alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AP-HP Pitié Salpetrière
Paris, 75013, France
-
CHRU Lille
Lille, 59037, France
-
CHU Poitiers
Poitiers, 86000, France
-
CHU Rennes
Rennes, 35033, France
-
CHU St Etienne
Saint-Etienne, 42055, France
-
CHU de BORDEAUX
Bordeaux, Bordeaux, 33404, France
-
CHU de GRENOBLE ALPES
Grenoble, Alpes, 38043, France
-
CHU de REIMS
Reims, Reims, 51092, France
-
Hôpital Privé Jean Mermoz
Lyon, 69008, France
Conditions
Explore the condition pages connected to this study.